Study of the combination gemcitabine and trastuzumab in the treatment of HER2+metastatic breast cancer

被引：0
|
作者：
Menjon-Beltran, S. [1 ]
Olivencia-Dueso, R. [1 ]
Gonzalez-Jimenez, E. [1 ]
Titos, M. J. [1 ]
机构：
[1] Hosp Univ Virgen Nieves, Unidad Ginecol Oncol, Granada, Spain
来源：
BREAST CANCER RESEARCH | 2007年 / 9卷 / 01期
关键词：
Gemcitabine; Trastuzumab; Clinical Benefit; Stable Disease; Metastatic Breast Cancer;
D O I：
10.1186/bcr1717
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Vinflunine in combination with trastuzumab: an active combination in the treatment of HER2 positive metastatic breast cancer
    Paridaens, R.
    Wildiers, H.
    Dalenc, F.
    Rixe, O.
    Roche, H.
    Cadic, V
    F-M, Delgado
    BREAST CANCER RESEARCH AND TREATMENT, 2007, 106 : S70 - S70
  • [22] Updated Austrian treatment algorithm in HER2+metastatic breast cancer
    Bartsch, Rupert
    Gampenrieder, Simon Peter
    Rinnerthaler, Gabriel
    Petru, Edgar
    Egle, Daniel
    Petzer, Andreas
    Balic, Marija
    Pluschnig, Ursula
    Sliwa, Thamer
    Singer, Christian
    WIENER KLINISCHE WOCHENSCHRIFT, 2022, 134 (1-2) : 63 - 72
  • [23] COST-EFFECTIVENESS MODEL OF PERTUZUMAB IN COMBINATION WITH TRASTUZUMAB AND DOCETAXEL COMPARED WITH TRASTUZUMAB IN COMBINATION WITH DOCETAXEL FOR THE 1ST LINE TREATMENT OF HER2+METASTATIC BREAST CANCER IN COLOMBIA
    Saenz, Ariza S. A.
    VALUE IN HEALTH, 2014, 17 (07) : A631 - A631
  • [24] COST-EFFECTIVENESS ANALYSIS OF TRASTUZUMAB DERUXTECAN FOR PATIENTS WITH HER2+METASTATIC BREAST CANCER
    Mudumba, R.
    Chan, H.
    Cheng, Y. Y.
    Wang, C. C.
    Correia, L.
    Ballreich, J.
    Levy, J.
    VALUE IN HEALTH, 2022, 25 (12) : S95 - S95
  • [25] A phase 1 study of vinflunine in combination with trastuzumab for the treatment for HER2-positive metastatic breast cancer
    Paridaens, R.
    Rixe, O.
    Pinel, M. C.
    Wildiers, H.
    Zorza, G.
    Ferre, P.
    Roche, H.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012, 70 (04) : 503 - 511
  • [26] A phase 1 study of vinflunine in combination with trastuzumab for the treatment for HER2-positive metastatic breast cancer
    R. Paridaens
    O. Rixe
    M. C. Pinel
    H. Wildiers
    G. Zorza
    P. Ferré
    H. Roche
    Cancer Chemotherapy and Pharmacology, 2012, 70 : 503 - 511
  • [27] Trastuzumab and vinorelbine combination in the treatment of Her2 positive metastatic breast cancer.
    Bayo, J
    Mayordomo, JI
    Sanchez-Rovira, P
    Perez-Carrion, R
    Illaramendi, J
    Flores, EG
    Bueno, JMG
    Vazquez, MR
    Crespo, C
    Palomo, AG
    Huelva, HJRJ
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 67S - 67S
  • [28] Larotaxel (L) in combination with trastuzumab in patients with HER2+metastatic breast cancer (MBC): Interim analysis of an open phase II label study
    Dieras, V.
    Viens, P.
    Veyret, C.
    Romieu, G.
    Awada, A.
    Lidbrink, E.
    Bonnefoi, H.
    Mery-Mignard, D.
    Dalenc, F.
    Roche, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [29] Evolving HER2+Metastatic Breast Cancer Landscape
    Seidman, Andrew D.
    Bardia, Aditya
    Pegram, Mark
    Rao, Ruta
    ONCOLOGY-NEW YORK, 2021, 35 (12): : 839 - 842
  • [30] Biweekly combination of trastuzumab, docetaxel and gemcitabine for HER2-positive metastatic breast cancer: results of a Phase II GOIM study
    Orlando, Laura
    Giotta, Francesco
    Lorusso, Vito
    De Vita, Ferdinando
    Filippelli, Gianfranco
    Maiello, Evaristo
    Riccardi, Ferdinando
    Pappagallo, Giovanni Luigi
    Fedele, Palma
    Gebbia, Nicola
    Verderame, Francesco
    Barni, Sandro
    Blasi, Livio
    Pisconti, Salvatore
    Colucci, Giuseppe
    Cinieri, Saverio
    FUTURE ONCOLOGY, 2014, 10 (05) : 725 - 733
12345